PROVIT The Influence of Probiotics on Body and Mind in Individuals With Psychiatric Disorders
Primary Purpose
Mood Disorders, Depression
Status
Unknown status
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
Probiotics and vitamin B7
Placebo and vitamin B7
Sponsored by
About this trial
This is an interventional supportive care trial for Mood Disorders
Eligibility Criteria
Inclusion Criteria:
- diagnosis of mood (affective) disorders (ICD 10 F3xx)
- or neurotic, stress-related and somatoform disorders (ICD 10 F4xx),
- inpatient treatment at the ward in the first floor of the Department of Psychiatry and Psychotherapeutic Medicine in Graz
- written informed consent
Exclusion Criteria:
- acute suicidality and potential dangers for themselves or other persons
- intake of antibiotics during the last month
- intake of food supplement with probiotic cultures or butyrate during the last year
- persons who are incapable of giving consent
- dementia (Mini Mental Status Examination ≤ 20)
- mental retardation
- misuse of laxatives and diuretics
- acute or chronical gastrointestinal infection or diseases
- pregnancy or breastfeeding period
- acute tumor or autoimmune diseases
- organic brain/mental disorders
- active drug or alcohol abuse
Sites / Locations
- Medical University of Graz, Department of Psychiatry and Psychotherapeutic Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Intervention group
Control group
Arm Description
Probiotics and vitamin B7
Placebo and vitamin B7
Outcomes
Primary Outcome Measures
Changes in fecal butyrate levels [μmol/g]
Stool diagnostics is performed by Biovis
Changes in fecal zonulin levels [ng/ml]
Stool diagnostics is performed by Biovis
Changes in gastrointestinal quality of life [total score]
Gastrointestinal quality of life index (Eypasch E, Wood-Dauphinée S, Williams JI, et al. The Gastrointestinal Quality of Life Index. A clinical index for measuring patient status in gastroenterologic surgery. Chirurg. 1993;64(4):264-274.)
Changes in depressive symptoms [HAM-D - total score]
Clinical assessment of Hamilton Rating Scale for Depression (Hamilton, M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 1960;23: 56-62)
Changes in depressive symptoms [BDI-II - total score]
Self-rating of depressive symptoms by the patient with Beck Depression Inventory-II (Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. Journal of Personality Assessment. 1996;67 (3): 588-97.)
Changes in overall psychological distress [SCL-90-R9 - GSI]
GSI - global severity index of Symptom Checklist-90-Revised (Franke, GH. SCL-90-R. Die Symptom-Checkliste von Derogatis-Deutsche Version. Göttingen: Beltz, 1995.)
Secondary Outcome Measures
Full Information
NCT ID
NCT03300440
First Posted
September 28, 2017
Last Updated
September 17, 2018
Sponsor
Medical University of Graz
1. Study Identification
Unique Protocol Identification Number
NCT03300440
Brief Title
PROVIT The Influence of Probiotics on Body and Mind in Individuals With Psychiatric Disorders
Official Title
The Influence of Probiotics on Body and Mind in Individuals With Psychiatric Disorders - a Clinical Study
Study Type
Interventional
2. Study Status
Record Verification Date
September 2018
Overall Recruitment Status
Unknown status
Study Start Date
June 21, 2017 (Actual)
Primary Completion Date
August 1, 2018 (Actual)
Study Completion Date
June 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of Graz
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The aim of this study is to explore the effects of probiotics in individuals with a clinically relevant depression on psychiatric symptoms and cognition, inflammatory parameters, as well as gene-expression. The study is conducted as a placebo-controlled, randomized, double-blind, prospective, monocentric clinical study, with a two-arm parallel group design. Individuals in the intervention group receive the multispecies probiotics "Omnibiotics Stress Repair" in addition to vitamin B7, while individuals in the control group receive "Placebo" in addition to vitamin B7.
Detailed Description
The study takes places at the Medical University of Graz, Department of Psychiatry and Psychotherapeutic Medicine. Individuals that start inpatient treatment at the ward in the first floor of the Department because of a major depressive episode are eligible. After inclusion into the study, the participants are asked to fill in different self-rating questionnaires (Becks-Depression Inventory-II BDI-II, Symptom Checklist-90-Revised SCL-90-R, Manie-Selbstbeurteilungsskala german adaptation of Self-Report manic inventory (SRMI) - MSS, food frequency questionnaire). General data are explored routinely, as well as a diagnostic interview (MINI - mini international neuropsychiatric interview, German version 5.0) is performed during the stay at the hospital. Participants are asked to provide a stool probe as soon as possible.
At the day after admission, fasting blood is taken (100ml). Routine parameters are further analyzed at the local laboratory, while the rest is stored at -80 degree for later analyzes. Afterwards a cognitive test-battery is performed to measure verbal learning and memory, information processing speed, cognitive flexibility and working memory capacity.
After one week a further stool probe is taken, to measure possible changes in dietary habits due to the stay at the hospital. Antidepressive treatment at the hospital is continued as treatment as usual.
At the end participants go through a similar cognitive test battery as at the beginning and are asked to fill in the same self-rating questionnaires. If participants are discharged before day 28 they are given their own preparation and instructed to take it at home in the exact same manner. An outpatient appointment at the end of the preparation intake is arranged to collect the fasting blood and stool sample and to perform the cognitive assessment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mood Disorders, Depression
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention group
Arm Type
Experimental
Arm Description
Probiotics and vitamin B7
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
Placebo and vitamin B7
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotics and vitamin B7
Other Intervention Name(s)
Omnibiotics Stress Repair
Intervention Description
Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form (7,5 x 109 CFU) Bacteria strains: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactobacillus acidophilus W22 Lactobacillus casei W56 Lactobacillus paracasei W20 Lactobacillus plantarum W62 Lactobacillus salivarius W24 Lactococcus lactis W19 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo and vitamin B7
Other Intervention Name(s)
Biotin
Intervention Description
Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
Primary Outcome Measure Information:
Title
Changes in fecal butyrate levels [μmol/g]
Description
Stool diagnostics is performed by Biovis
Time Frame
28 (+/- 2) days
Title
Changes in fecal zonulin levels [ng/ml]
Description
Stool diagnostics is performed by Biovis
Time Frame
28 (+/- 2) days
Title
Changes in gastrointestinal quality of life [total score]
Description
Gastrointestinal quality of life index (Eypasch E, Wood-Dauphinée S, Williams JI, et al. The Gastrointestinal Quality of Life Index. A clinical index for measuring patient status in gastroenterologic surgery. Chirurg. 1993;64(4):264-274.)
Time Frame
28 (+/- 2) days
Title
Changes in depressive symptoms [HAM-D - total score]
Description
Clinical assessment of Hamilton Rating Scale for Depression (Hamilton, M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 1960;23: 56-62)
Time Frame
28 (+/- 2) days
Title
Changes in depressive symptoms [BDI-II - total score]
Description
Self-rating of depressive symptoms by the patient with Beck Depression Inventory-II (Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. Journal of Personality Assessment. 1996;67 (3): 588-97.)
Time Frame
28 (+/- 2) days
Title
Changes in overall psychological distress [SCL-90-R9 - GSI]
Description
GSI - global severity index of Symptom Checklist-90-Revised (Franke, GH. SCL-90-R. Die Symptom-Checkliste von Derogatis-Deutsche Version. Göttingen: Beltz, 1995.)
Time Frame
28 (+/- 2) days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
diagnosis of mood (affective) disorders (ICD 10 F3xx)
or neurotic, stress-related and somatoform disorders (ICD 10 F4xx),
inpatient treatment at the ward in the first floor of the Department of Psychiatry and Psychotherapeutic Medicine in Graz
written informed consent
Exclusion Criteria:
acute suicidality and potential dangers for themselves or other persons
intake of antibiotics during the last month
intake of food supplement with probiotic cultures or butyrate during the last year
persons who are incapable of giving consent
dementia (Mini Mental Status Examination ≤ 20)
mental retardation
misuse of laxatives and diuretics
acute or chronical gastrointestinal infection or diseases
pregnancy or breastfeeding period
acute tumor or autoimmune diseases
organic brain/mental disorders
active drug or alcohol abuse
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eva Reininghaus, PD, MD
Organizational Affiliation
Medical University of Graz, Department of Psychiatry and Psychotherapeutic Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University of Graz, Department of Psychiatry and Psychotherapeutic Medicine
City
Graz
State/Province
Styria
ZIP/Postal Code
8036
Country
Austria
12. IPD Sharing Statement
Learn more about this trial
PROVIT The Influence of Probiotics on Body and Mind in Individuals With Psychiatric Disorders
We'll reach out to this number within 24 hrs